Revolution in the laboratory: Roche brings automated mass spectrometry to Austria!

Revolution in the laboratory: Roche brings automated mass spectrometry to Austria!

Roche in Austria, which heralds a new era of mass spectrometry into routine laboratories. This innovative solution brings mass spectrometry into an environment that was previously limited by complexity and a lack of automation. The COBAS® MASS SPEC solution offers a fully automatic, integrated and standardized workflow based on IVDR-compliant tests. This enables precise and quick diagnostics, which is of crucial importance in today's world.

The heart of this solution is the Cobas® I 601 analysis module, which is able to carry out up to 100 injections per hour. The test results are provided 40 minutes after the start. In addition, over 60 analytes in areas such as steroid hormones, vitamin D metabolites and immunosuppressants are to be offered in the coming years, which underlines the flexibility and applicability of the technology. that mass spectrometry is considered the diagnostic "gold standard" for different clinical applications.

The introduction of the Cobas® Mass Spec solution is in the context that laboratories are increasingly under pressure to process more samples faster and more precisely. Roche's solution not only includes the hardware and software, but also Ragenz Packs, System Reaffen and Consumables to ensure complete integration into clinical chemistry and immunology. Roche informs that the technology is an integration of four different technologies-ISE (ionensing electrodes), clinical chemistry, immunchemy and mass spectrometry Platform made possible.

Roche already has a track record in the provision of pioneering laboratory solutions and continuously invests in the development of innovative diagnostic technologies. Mass spectrometry provides doctors more extensive information in shorter periods of time, which is of great importance for patient care. As Roche emphasizes , the complex technology of mass spectrometry in clinical central laboratories has so far not been adequately used. The COBAS® Mass Spec solution aims to close this gap and offer an end-to-end solution for clinical mass spectrometry tests.

By complete automation from sample preparation to the result interpretation in the Random Access procedure, laboratory processes should be significantly streamlined and standardized. This aims to increase the patient throughput and ensure consistent results, which is ultimately reduced to pressure on the laboratories.